1. Home
  2. RFM vs ICCM Comparison

RFM vs ICCM Comparison

Compare RFM & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFM
  • ICCM
  • Stock Information
  • Founded
  • RFM 2020
  • ICCM 2006
  • Country
  • RFM United States
  • ICCM Israel
  • Employees
  • RFM N/A
  • ICCM N/A
  • Industry
  • RFM Finance/Investors Services
  • ICCM
  • Sector
  • RFM Finance
  • ICCM
  • Exchange
  • RFM Nasdaq
  • ICCM Nasdaq
  • Market Cap
  • RFM 85.8M
  • ICCM 61.0M
  • IPO Year
  • RFM N/A
  • ICCM N/A
  • Fundamental
  • Price
  • RFM $14.15
  • ICCM $1.05
  • Analyst Decision
  • RFM
  • ICCM Strong Buy
  • Analyst Count
  • RFM 0
  • ICCM 1
  • Target Price
  • RFM N/A
  • ICCM $2.50
  • AVG Volume (30 Days)
  • RFM 20.7K
  • ICCM 258.0K
  • Earning Date
  • RFM 01-01-0001
  • ICCM 05-28-2025
  • Dividend Yield
  • RFM 9.74%
  • ICCM N/A
  • EPS Growth
  • RFM N/A
  • ICCM N/A
  • EPS
  • RFM N/A
  • ICCM N/A
  • Revenue
  • RFM N/A
  • ICCM $3,273,000.00
  • Revenue This Year
  • RFM N/A
  • ICCM $85.75
  • Revenue Next Year
  • RFM N/A
  • ICCM $189.92
  • P/E Ratio
  • RFM N/A
  • ICCM N/A
  • Revenue Growth
  • RFM N/A
  • ICCM 0.34
  • 52 Week Low
  • RFM $12.89
  • ICCM $0.48
  • 52 Week High
  • RFM $16.41
  • ICCM $1.66
  • Technical
  • Relative Strength Index (RSI)
  • RFM 45.01
  • ICCM 46.97
  • Support Level
  • RFM $14.01
  • ICCM $0.89
  • Resistance Level
  • RFM $14.18
  • ICCM $1.14
  • Average True Range (ATR)
  • RFM 0.12
  • ICCM 0.07
  • MACD
  • RFM -0.02
  • ICCM 0.01
  • Stochastic Oscillator
  • RFM 27.65
  • ICCM 64.00

About RFM RiverNorth Flexible Municipal Income Fund Inc.

RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: